Non-small-cell lung cancer: how to manage EGFR-mutated disease

The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped the therapeutic algorithm both in the first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Pecci, Federica, Cantini, Luca, Metro, Giulio, Ricciuti, Biagio, Lamberti, Giuseppe, Farooqi, Ammad Ahmad, Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354708/
https://www.ncbi.nlm.nih.gov/pubmed/35975029
http://dx.doi.org/10.7573/dic.2022-4-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354708/
https://www.ncbi.nlm.nih.gov/pubmed/35975029
http://dx.doi.org/10.7573/dic.2022-4-1

Ejemplares similares